Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry
vs
history
Cash to Debt 5.26
PXSLY's Cash to Debt is ranked higher than
74% of the 775 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.08 vs. PXSLY: 5.26 )
PXSLY' s 10-Year Cash to Debt Range
Min: 3.37   Max: No Debt
Current: 5.26

Equity to Asset 0.61
PXSLY's Equity to Asset is ranked higher than
68% of the 728 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.60 vs. PXSLY: 0.61 )
PXSLY' s 10-Year Equity to Asset Range
Min: 0.61   Max: 0.98
Current: 0.61

0.61
0.98
F-Score: 4
Z-Score: -4.07
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
Operating margin (%) -1512.51
PXSLY's Operating margin (%) is ranked lower than
57% of the 741 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 10.25 vs. PXSLY: -1512.51 )
PXSLY' s 10-Year Operating margin (%) Range
Min: -1310600   Max: -1512.51
Current: -1512.51

-1310600
-1512.51
Net-margin (%) -1344.98
PXSLY's Net-margin (%) is ranked lower than
57% of the 741 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.16 vs. PXSLY: -1344.98 )
PXSLY' s 10-Year Net-margin (%) Range
Min: -1023200   Max: -1344.98
Current: -1344.98

-1023200
-1344.98
ROE (%) -64.12
PXSLY's ROE (%) is ranked lower than
54% of the 752 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 6.97 vs. PXSLY: -64.12 )
PXSLY' s 10-Year ROE (%) Range
Min: -64.6   Max: -5.03
Current: -64.12

-64.6
-5.03
ROA (%) -38.78
PXSLY's ROA (%) is ranked lower than
52% of the 777 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.87 vs. PXSLY: -38.78 )
PXSLY' s 10-Year ROA (%) Range
Min: -48.38   Max: -4.93
Current: -38.78

-48.38
-4.93
ROC (Joel Greenblatt) (%) -194.94
PXSLY's ROC (Joel Greenblatt) (%) is ranked higher than
50% of the 772 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 15.60 vs. PXSLY: -194.94 )
PXSLY' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -897.19   Max: -124.99
Current: -194.94

-897.19
-124.99
EBITDA Growth (%) -14.80
PXSLY's EBITDA Growth (%) is ranked higher than
56% of the 618 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 4.60 vs. PXSLY: -14.80 )
PXSLY' s 10-Year EBITDA Growth (%) Range
Min: -14.8   Max: 71
Current: -14.8

-14.8
71
EPS Growth (%) -12.60
PXSLY's EPS Growth (%) is ranked higher than
63% of the 597 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 5.40 vs. PXSLY: -12.60 )
PXSLY' s 10-Year EPS Growth (%) Range
Min: -12.6   Max: 122.4
Current: -12.6

-12.6
122.4
» PXSLY's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Insider Trades

Latest Guru Trades with PXSLY

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)



No Insider Trades Found!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 0.20
PXSLY's P/B is ranked higher than
99% of the 807 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.38 vs. PXSLY: 0.20 )
PXSLY' s 10-Year P/B Range
Min: 0.24   Max: 6.12
Current: 0.2

0.24
6.12
P/S 5.00
PXSLY's P/S is ranked higher than
55% of the 807 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.70 vs. PXSLY: 5.00 )
PXSLY' s 10-Year P/S Range
Min: 5.3   Max: 312
Current: 5

5.3
312
EV-to-EBIT 0.70
PXSLY's EV-to-EBIT is ranked higher than
100% of the 807 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 33.72 vs. PXSLY: 0.70 )
PXSLY' s 10-Year EV-to-EBIT Range
Min: 0   Max: 0
Current: 0.7

Current Ratio 8.35
PXSLY's Current Ratio is ranked lower than
83% of the 625 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.47 vs. PXSLY: 8.35 )
PXSLY' s 10-Year Current Ratio Range
Min: 5.94   Max: 44.5
Current: 8.35

5.94
44.5
Quick Ratio 8.10
PXSLY's Quick Ratio is ranked lower than
83% of the 625 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.81 vs. PXSLY: 8.10 )
PXSLY' s 10-Year Quick Ratio Range
Min: 5.83   Max: 44.5
Current: 8.1

5.83
44.5

Valuation & Return

vs
industry
vs
history
Price/Net Cash 0.83
PXSLY's Price/Net Cash is ranked higher than
100% of the 807 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 9999.00 vs. PXSLY: 0.83 )
PXSLY' s 10-Year Price/Net Cash Range
Min: 1.72   Max: 9.33
Current: 0.83

1.72
9.33
Price/Net Current Asset Value 0.63
PXSLY's Price/Net Current Asset Value is ranked higher than
100% of the 807 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 9999.00 vs. PXSLY: 0.63 )
PXSLY' s 10-Year Price/Net Current Asset Value Range
Min: 1.72   Max: 9.33
Current: 0.63

1.72
9.33
Price/Tangible Book 0.28
PXSLY's Price/Tangible Book is ranked higher than
100% of the 807 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 5.53 vs. PXSLY: 0.28 )
PXSLY' s 10-Year Price/Tangible Book Range
Min: 0.78   Max: 7.86
Current: 0.28

0.78
7.86
Price/Median PS Value 0.05
PXSLY's Price/Median PS Value is ranked higher than
100% of the 807 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.26 vs. PXSLY: 0.05 )
PXSLY' s 10-Year Price/Median PS Value Range
Min: 0.13   Max: 1.98
Current: 0.05

0.13
1.98
Earnings Yield (Greenblatt) 142.90
PXSLY's Earnings Yield (Greenblatt) is ranked higher than
98% of the 641 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 4.70 vs. PXSLY: 142.90 )
PXSLY' s 10-Year Earnings Yield (Greenblatt) Range
Min: 0   Max: 2093.4
Current: 142.9

0
2093.4
Forward Rate of Return (Yacktman) -283.35
PXSLY's Forward Rate of Return (Yacktman) is ranked lower than
55% of the 633 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.43 vs. PXSLY: -283.35 )
PXSLY' s 10-Year Forward Rate of Return (Yacktman) Range
Min: 0   Max: 0
Current: -283.35

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Major
Compare:GSK, JNJ, PFE, RHHBY, NVS » details
Traded in other countries:PXS.Australia, UUD.Germany
Pharmaxis Limited is an Australian specialty pharmaceutical company involved in the research, development and commercialization of healthcare products for chronic respiratory and immune diseases. The company produces Aridol, a powder which is used for the diagnosis and management of asthma and chronic obstructive pulmonary diseases. The company has sales and marketing group in Australia and has appointed marketing and distribution partners for certain European and Asian territories with respect to the marketing and sale of Aridol. They also manufacture Bronchitol, a drug used for chronic obstructive lung diseases like cystic fibrosis, bronchiectasis, and chronic bronchitis. The company has established offices In order to commercialize this product.

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Add Notes, Comments or Ask Questions

User Comments

No comment yet

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK